Physician profile
Scott Gioe
NPI 1538255815
$6,703.59
in general payments reported to CMS, 2019-2025
34 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $155 · 2021: $845 · 2022: $861 · 2023: $1,355 · 2024: $1,227 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,129.35 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,874.10 | 2021-2025 | |
| Janssen Biotech, INC. | $803.92 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $445.07 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $374.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $364.28 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $322.12 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.83 | 2019-2022 | |
| Celgene Corporation | $280.55 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $263.04 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $172.23 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $143.53 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $143.01 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $132.72 | 2022-2025 | |
| Evoke Pharma, INC. | $122.09 | 2021-2024 | Gimoti |
| Lilly USA, LLC | $110.59 | 2024-2025 | Omvoh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $103.06 | 2019-2023 | Sucraid |
| Celltrion USA INC. | $81.28 | 2024-2025 | Vegzelma |
| Daiichi Sankyo INC. | $74.92 | 2020-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $71.08 | 2025 | Dupixent |
| Shionogi INC | $70.88 | 2019 | |
| Pharmacosmos Therapeutics INC. | $65.15 | 2022-2023 | Monoferric |
| Aimmune Therapeutics, INC. | $57.66 | 2025 | Zenpep |
| Allergan, INC. | $54.81 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $54.65 | 2023-2025 | Terlivaz |
| Pfizer INC. | $45.30 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $38.13 | 2019-2023 | Dificid |
| Orphalan INC | $24.86 | 2025 | Cuvrior |
| Concordia Pharmaceuticals INC. | $20.03 | 2019 | |
| Boston Scientific Corporation | $17.12 | 2023 | Radial Jaw 4 |
| Echosens North America, INC. | $15.38 | 2021 | |
| Amgen INC. | $14.36 | 2023 | Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $13.31 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gioe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.